SLC16A3（MCT4）在肺腺癌中的预后价值及其临床意义
Prognostic Value of SLC16A3(MCT4) in Lung Adenocarcinoma and Its Clinical Significance.
作者信息
Xue Lei, Liu Jinyuan, Xie Jiaheng, Luo Jinhua
机构信息
Department of Thoracic Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, 210029, People's Republic of China.
Department of Burn and Plastic Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, 210029, People's Republic of China.
出版信息
Int J Gen Med. 2021 Nov 17;14:8413-8425. doi: 10.2147/IJGM.S337615. eCollection 2021.
BACKGROUND
Currently, lung adenocarcinoma is the most common form of lung cancer. Although the pathogenesis of lung adenocarcinoma is progressing rapidly, the mortality rate of lung adenocarcinoma is still high. Therefore, it is necessary to search for a new biomarker to guide the prognosis of lung adenocarcinoma.
METHODS
The significance of SLC16A3 in lung adenocarcinoma was investigated by multi-database analysis. GEPIA, UALCAN, TIMER, Cbioportal, and R software were used for research.
RESULTS
Our study found that SLC16A3 was highly expressed in lung adenocarcinoma and was associated with poor prognosis. Further studies have shown that SLC16A3 is involved in some metabolic pathways. Not only that, SLC16A3 is associated with immune cell infiltration and tumor mutation burden (TMB).
CONCLUSION
SLC16A3 has good prognostic significance in lung adenocarcinoma, based on which to explore treatment options may improve the prognosis of patients.
背景
目前，肺腺癌是肺癌最常见的类型。尽管肺腺癌的发病机制进展迅速，但肺腺癌的死亡率仍然很高。因此，有必要寻找一种新的生物标志物来指导肺腺癌的预后。
方法
通过多数据库分析研究SLC16A3在肺腺癌中的意义。使用GEPIA、UALCAN、TIMER、Cbioportal和R软件进行研究。
结果
我们的研究发现SLC16A3在肺腺癌中高表达，且与预后不良相关。进一步研究表明，SLC16A3参与某些代谢途径。不仅如此，SLC16A3与免疫细胞浸润和肿瘤突变负荷（TMB）相关。
结论
SLC16A3在肺腺癌中具有良好的预后意义，基于此探索治疗方案可能改善患者的预后。
Zotero 插件